Retinal vascular occlusion affects the eye, specifically the retina. The retina is the light-sensitive layer of tissue that lines the back of your eye. It’s covered with special cells called rods and ...

RETINAL artery occlusion (RAO) may signal an increased risk of future cardiovascular events, according to data from a large ...

Central retinal artery occlusion (CRAO) is caused by a thrombus or embolism in the central retinal artery. Mainly occurring in the optic nerve head, it is an ophthalmological emergency often resulting ...

New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.

The coronavirus disease 2019 (COVID-19) has been reported to affect vascular networks including the eye. However, evidence on the causal relationship between COVID-19 infection and retinal vascular ...

The risk for retinal vein occlusion (RVO) may be increased in the six months following COVID-19 infection, according to a study published online April 14 in JAMA Ophthalmology. Bobeck S. Modjtahedi, M ...

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with retinal vein occlusions have an increased ...

NEW YORK, July 30 (Reuters) - Roche Holding AG's eye disease drug Lucentis proved effective in helping to improve vision in patients suffering from a condition known as central retinal vein occlusion, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...

Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

LOS ANGELES, July 2 (Reuters) - Monthly injections of Roche Holding AG's Lucentis can significantly improve sight in people with retinal vein occlusion, which leads to vision loss, according to ...